NYSE American accepts Picard Medical (NYSE American: PMI) continued listing compliance plan
Rhea-AI Filing Summary
Picard Medical, Inc. reported that NYSE American has accepted its plan to regain compliance with the exchange’s continued listing standards under Sections 1003(a)(i) and (ii). Acceptance allows the company’s common stock to continue trading on NYSE American while it works toward milestones in the compliance plan.
The company had previously reported stockholders’ equity of $3.8 million as of December 31, 2025 and a stockholders’ deficit of $(1.4) million as of March 31, 2026, along with losses in three of its four most recent fiscal years ended December 31, 2025. Picard Medical has been granted a compliance period through November 8, 2027 and is subject to a maximum period of 18 months from the original noncompliance notice to regain compliance, with periodic NYSE American review.
Positive
- NYSE American grants a listing compliance period through November 8, 2027.
- Picard Medical’s common stock continues trading on NYSE American under a compliance plan.
Negative
- Company reported a stockholders’ deficit of $(1.4) million as of March 31, 2026.
- Reported losses in three of its four most recent fiscal years ended December 31, 2025.
Insights
Analyzing...
8-K Event Classification
3 items: 3.01, 8.01, 9.01
3 items
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice or transferred its listing to a different exchange.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Stockholders’ equity: $3.8 million
Stockholders’ deficit: $(1.4) million
Loss history: Losses in 3 of 4 fiscal years
+3 more
6 metrics
Stockholders’ equity
$3.8 million
As of December 31, 2025, used in assessing listing compliance
Stockholders’ deficit
$(1.4) million
As of March 31, 2026, cited in NYSE American notice
Loss history
Losses in 3 of 4 fiscal years
Three of four most recent fiscal years ended December 31, 2025
Compliance period end date
November 8, 2027
Date through which NYSE American granted compliance period
Maximum compliance window
18 months
Maximum period from original noncompliance notice to regain compliance
SynCardia Total Artificial Heart implants
More than 2,100 implants
Implants performed at hospitals across 27 countries
Key Terms
continued listing standards, stockholders’ deficit, compliance period, forward-looking statements, +1 more
5 terms
continued listing standards regulatory
"to regain compliance with the NYSE American’s continued listing standards"
Ongoing rules a stock exchange requires a listed company to meet to keep its shares trading publicly, such as minimum share price, market value, timely financial reports, and governance practices. Think of it as a membership checklist for a club: falling short can lead to warnings or removal from the exchange, which can sharply reduce liquidity, investor confidence, and a stock’s value. Investors watch these standards to gauge regulatory risk and the stability of their holdings.
stockholders’ deficit financial
"reported (ii) stockholders’ deficit of $(1.4) million as of March 31, 2026"
Stockholders’ deficit is the situation where a company’s total liabilities exceed its total assets, so the book value attributed to shareholders is negative. Think of it like a household with more outstanding debts than the value of its house and possessions—this can signal past losses or aggressive payouts and raises the risk that shareholders may be wiped out, diluted, or face difficulty when the company needs new financing. Investors watch it as a warning about solvency and long‑term financial health.
compliance period regulatory
"The Company has been granted a compliance period through November 8, 2027"
A compliance period is a defined stretch of time during which a company must meet specific legal, regulatory, or contractual rules and reporting requirements. Think of it like a scheduled inspection window or a homework deadline: failing to satisfy the rules within that window can trigger fines, restrictions, or extra oversight, so investors watch compliance periods as signals of near-term legal risk, potential costs, and impacts on a company’s operations or cash flow.
forward-looking statements regulatory
"This press release includes forward-looking statements within the meaning"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Private Securities Litigation Reform Act of 1995 regulatory
"within the meaning of the Private Securities Litigation Reform Act of 1995"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
Why was Picard Medical (PMI) out of compliance with NYSE American listing standards?
Picard Medical was out of compliance because it reported stockholders’ equity of $3.8 million as of December 31, 2025, a stockholders’ deficit of $(1.4) million as of March 31, 2026, and losses in three of its four most recent fiscal years.
What did NYSE American decide about Picard Medical (PMI)’s continued listing?
NYSE American accepted Picard Medical’s compliance plan to regain listing standards under Sections 1003(a)(i) and (ii), allowing its common stock to continue trading while the company works toward plan milestones under ongoing exchange review.
How long does Picard Medical (PMI) have to regain NYSE American compliance?
Picard Medical has a compliance period through November 8, 2027 and is subject to a maximum 18‑month period from the original noncompliance notice to regain compliance, with NYSE American conducting periodic reviews of its progress.
On which exchange does Picard Medical (PMI) trade and under what symbol?
Picard Medical’s common stock trades on the NYSE American under the ticker symbol “PMI”. Acceptance of its compliance plan allows the company to continue listing and trading its shares on that exchange during the compliance period.
What is Picard Medical (PMI)’s core business through its SynCardia subsidiary?
Through SynCardia Systems, Picard Medical develops and commercializes the SynCardia Total Artificial Heart, an implantable system for end-stage heart failure. More than 2,100 implants have been performed at hospitals across 27 countries worldwide.